CN103370318B - 取代的咪唑并哒嗪 - Google Patents
取代的咪唑并哒嗪 Download PDFInfo
- Publication number
- CN103370318B CN103370318B CN201180054217.5A CN201180054217A CN103370318B CN 103370318 B CN103370318 B CN 103370318B CN 201180054217 A CN201180054217 A CN 201180054217A CN 103370318 B CN103370318 B CN 103370318B
- Authority
- CN
- China
- Prior art keywords
- amino
- alkyl
- imidazo
- cyclopropyl
- methylbenzamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 Cc(cc1*)n[n]2c1ncc2* Chemical compound Cc(cc1*)n[n]2c1ncc2* 0.000 description 72
- NPMUHWKZTXBCQT-GQCTYLIASA-N C=C/C(/O)=C\CCCl Chemical compound C=C/C(/O)=C\CCCl NPMUHWKZTXBCQT-GQCTYLIASA-N 0.000 description 1
- YDNBEPLGELBMAM-UHFFFAOYSA-N C=S(CCN)(N1CCOCC1)=O Chemical compound C=S(CCN)(N1CCOCC1)=O YDNBEPLGELBMAM-UHFFFAOYSA-N 0.000 description 1
- JNYRWLGEUOJZLC-BOPFTXTBSA-N CC(C([NH+](CCC(F)(F)F)[IH-])=C1)N(/C(/c(c(OC)c2)ccc2C(NC2CC2)=O)=C\N)N=C1Cl Chemical compound CC(C([NH+](CCC(F)(F)F)[IH-])=C1)N(/C(/c(c(OC)c2)ccc2C(NC2CC2)=O)=C\N)N=C1Cl JNYRWLGEUOJZLC-BOPFTXTBSA-N 0.000 description 1
- VPJAXAVXZHUJDD-UHFFFAOYSA-N CC(C)(C)OC(N(CCC(F)(F)F)C1=CC(OC2CCCC2)=NN2C1=NCC2)O Chemical compound CC(C)(C)OC(N(CCC(F)(F)F)C1=CC(OC2CCCC2)=NN2C1=NCC2)O VPJAXAVXZHUJDD-UHFFFAOYSA-N 0.000 description 1
- VVOJGSPBCUOHBX-GQCTYLIASA-N CC(C)(CNc1cc(/C=C/C)n[n]2c1ncc2-c(cc1)ccc1C(C1)=CC=C=C1C1CC1)O Chemical compound CC(C)(CNc1cc(/C=C/C)n[n]2c1ncc2-c(cc1)ccc1C(C1)=CC=C=C1C1CC1)O VVOJGSPBCUOHBX-GQCTYLIASA-N 0.000 description 1
- WLAOXGOAKAAJKZ-UHFFFAOYSA-O CC(C)(CNc1cc(OC2C=C(C)C=CC2F)n[n]2c1ncc2-c(cc1)cc(C)c1/C(/NC1=CC1)=[I]\C)[OH2+] Chemical compound CC(C)(CNc1cc(OC2C=C(C)C=CC2F)n[n]2c1ncc2-c(cc1)cc(C)c1/C(/NC1=CC1)=[I]\C)[OH2+] WLAOXGOAKAAJKZ-UHFFFAOYSA-O 0.000 description 1
- ITQAGWRCXRRJLY-UHFFFAOYSA-N CC(C)CNc1cc(Cl)n[n]2c1ncc2I Chemical compound CC(C)CNc1cc(Cl)n[n]2c1ncc2I ITQAGWRCXRRJLY-UHFFFAOYSA-N 0.000 description 1
- SIRKPVMIPAJYOR-UHFFFAOYSA-N CC(C1CC1)=N Chemical compound CC(C1CC1)=N SIRKPVMIPAJYOR-UHFFFAOYSA-N 0.000 description 1
- LXKVIJIJUYIUJM-UHFFFAOYSA-N CC(CC=C1C2C=CC(C3OCCO3)=CC2)=C2N1N=C(C1CC1)C=C2NCCC(C=C)(F)[I]=C Chemical compound CC(CC=C1C2C=CC(C3OCCO3)=CC2)=C2N1N=C(C1CC1)C=C2NCCC(C=C)(F)[I]=C LXKVIJIJUYIUJM-UHFFFAOYSA-N 0.000 description 1
- LUCSKEOYSBCTLD-UHFFFAOYSA-N CC(CCC(F)(F)F)C(C1)C(NCC2)N2N=C1OC1CCCC1 Chemical compound CC(CCC(F)(F)F)C(C1)C(NCC2)N2N=C1OC1CCCC1 LUCSKEOYSBCTLD-UHFFFAOYSA-N 0.000 description 1
- HLYYEVXPWUKYRH-OUEMKMGPSA-N CC1C(OC)=CC(C(F)(F)F)=CC[C@H]1/C(/C)=C\C Chemical compound CC1C(OC)=CC(C(F)(F)F)=CC[C@H]1/C(/C)=C\C HLYYEVXPWUKYRH-OUEMKMGPSA-N 0.000 description 1
- WTTIBXJSRYPTAD-UHFFFAOYSA-N CCCC(CC)(N)I Chemical compound CCCC(CC)(N)I WTTIBXJSRYPTAD-UHFFFAOYSA-N 0.000 description 1
- RKUVDTAEELSXOS-UHFFFAOYSA-N CS(C(CN)=C)(O)O Chemical compound CS(C(CN)=C)(O)O RKUVDTAEELSXOS-UHFFFAOYSA-N 0.000 description 1
- UCOOYJWVHVWKMO-AWDGVXSRSA-N C[C@@H]1C(/C(/C=N)=C\C(C)=C)=NC=C1C Chemical compound C[C@@H]1C(/C(/C=N)=C\C(C)=C)=NC=C1C UCOOYJWVHVWKMO-AWDGVXSRSA-N 0.000 description 1
- ZCBBRONAQNFCBF-DRNOCVAXSA-N C[C@H](C/C(/OC1C=CC(C)=CC1)=N\NC)NCCN(C)C Chemical compound C[C@H](C/C(/OC1C=CC(C)=CC1)=N\NC)NCCN(C)C ZCBBRONAQNFCBF-DRNOCVAXSA-N 0.000 description 1
- KVSINRKOLLCEKQ-BODHNVNISA-N C[C@H](C/C=C/C(NC1CC1)=C)/C=C/C Chemical compound C[C@H](C/C=C/C(NC1CC1)=C)/C=C/C KVSINRKOLLCEKQ-BODHNVNISA-N 0.000 description 1
- BRRXHMRHQVITFS-SNVBAGLBSA-N C[C@](C=C1SC)(N(C)[n]2c1ncc2C)Br Chemical compound C[C@](C=C1SC)(N(C)[n]2c1ncc2C)Br BRRXHMRHQVITFS-SNVBAGLBSA-N 0.000 description 1
- OQPLQWARMNXILR-QCXNYLOCSA-O Cc(cc(C1NC(/C(/NCCCC(F)(F)F)=C\C(Br)=[NH2+])=NC1)cc1)c1C(CC1CC1)=C Chemical compound Cc(cc(C1NC(/C(/NCCCC(F)(F)F)=C\C(Br)=[NH2+])=NC1)cc1)c1C(CC1CC1)=C OQPLQWARMNXILR-QCXNYLOCSA-O 0.000 description 1
- XQXBTZNOVKJSSA-UHFFFAOYSA-N NC(C1)=CCCC1O Chemical compound NC(C1)=CCCC1O XQXBTZNOVKJSSA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Paper (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10176134.4 | 2010-09-10 | ||
| EP10176134 | 2010-09-10 | ||
| EP11075022.1 | 2011-02-04 | ||
| EP11075022 | 2011-02-04 | ||
| EP11170775.8 | 2011-06-21 | ||
| EP11170775 | 2011-06-21 | ||
| EP11170771 | 2011-06-21 | ||
| EP11170771.7 | 2011-06-21 | ||
| PCT/EP2011/065368 WO2012032031A1 (en) | 2010-09-10 | 2011-09-06 | Substituted imidazopyridazines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103370318A CN103370318A (zh) | 2013-10-23 |
| CN103370318B true CN103370318B (zh) | 2016-04-20 |
Family
ID=44545741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180054217.5A Expired - Fee Related CN103370318B (zh) | 2010-09-10 | 2011-09-06 | 取代的咪唑并哒嗪 |
Country Status (38)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| EP2734205B1 (en) | 2011-07-21 | 2018-03-21 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
| CN104284896B (zh) * | 2012-03-14 | 2016-06-01 | 拜耳知识产权有限责任公司 | 取代的咪唑并哒嗪 |
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9573954B2 (en) | 2012-11-16 | 2017-02-21 | University Health Network | Pyrazolopyrimidine compounds |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| TW201437211A (zh) * | 2013-03-01 | 2014-10-01 | Bayer Pharma AG | 經取代咪唑并嗒□ |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| RS56034B1 (sr) | 2013-06-11 | 2017-09-29 | Bayer Pharma AG | Derivati prolekova supstituisanih triazolopiridina |
| CN105392484A (zh) * | 2013-06-13 | 2016-03-09 | 拜耳制药股份公司 | 咪唑并哒嗪衍生物与有丝分裂试剂的联用药用于治疗癌症 |
| CN103360399B (zh) * | 2013-08-02 | 2016-03-02 | 北京大学 | 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途 |
| GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| SG11201606869TA (en) * | 2014-02-21 | 2016-09-29 | Frost Biolog Inc | Antimitotic amides for the treatment of cancer and proliferative disorders |
| WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| TW201613927A (en) * | 2014-09-01 | 2016-04-16 | Bayer Pharma AG | Method for preparation of substituted imidazopyridazines |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MX373169B (es) | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| FI3283642T3 (fi) | 2015-04-17 | 2024-01-11 | Crossfire Oncology Holding B V | Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan |
| WO2016187028A1 (en) * | 2015-05-15 | 2016-11-24 | Celgene Avilomics Research, Inc. | Heteroaryl compounds, synthesis thereof, and intermediates thereto |
| BR112018010271A2 (pt) * | 2015-12-04 | 2018-11-27 | Exxonmobil Research And Engineering Company | material cristalino sintético emm-28, sua preparação e uso |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| AU2017299850B2 (en) * | 2016-07-18 | 2021-05-27 | University Health Network | Solid forms of TTK inhibitor |
| WO2018189185A1 (en) * | 2017-04-11 | 2018-10-18 | Straumann Holding Ag | Dental implant |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| ES2992256T3 (es) | 2018-05-08 | 2024-12-11 | Nippon Shinyaku Co Ltd | Compuestos de azabencimidazol y producto farmacéutico |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| NZ778055A (en) | 2019-02-12 | 2025-11-28 | Sumitomo Pharma America Inc | Formulations comprising heterocyclic protein kinase inhibitors |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CN111978325B (zh) * | 2019-05-22 | 2023-11-17 | 中国药科大学 | 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| BR112022008571A2 (pt) | 2019-11-13 | 2022-08-09 | Nippon Shinyaku Co Ltd | Composto de azabenzimidazol e medicamento |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR20240107189A (ko) * | 2021-12-15 | 2024-07-08 | 신라젠(주) | 신생물성 질환 치료에 사용하기 위한 약제학적 병용물 |
| EP4651950A1 (en) * | 2023-01-19 | 2025-11-26 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007038314A2 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| WO2011013729A1 (ja) * | 2009-07-30 | 2011-02-03 | オンコセラピー・サイエンス株式会社 | Ｔｔｋ阻害作用を有する縮合イミダゾール誘導体 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127566A0 (en) | 1996-08-28 | 1999-10-28 | Pfizer | Substituted 6,5-hetero- bicyclic derivatives |
| WO2001083481A1 (en) | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| US7132426B2 (en) | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| US20090023737A1 (en) | 2004-02-12 | 2009-01-22 | Neurogen Corporation | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| TW200804386A (en) * | 2005-11-10 | 2008-01-16 | Schering Corp | Imidazopyrazines as protein kinase inhibitors |
| TW200840584A (en) * | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
| US8546394B2 (en) * | 2007-04-17 | 2013-10-01 | Bristol-Myers Squibb Company | Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors |
| EP2217601A1 (en) | 2007-11-08 | 2010-08-18 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyridazines for use as protein kinase inhibitors |
| WO2009100375A1 (en) | 2008-02-06 | 2009-08-13 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| CN102413831B (zh) | 2009-04-29 | 2014-06-04 | 拜耳知识产权有限责任公司 | 取代的咪唑并喹喔啉 |
| CA2772790C (en) | 2009-09-04 | 2017-06-27 | Benjamin Bader | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| EP2343295A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| US9468642B2 (en) | 2010-03-18 | 2016-10-18 | Bayer Intellectual Property Gmbh | Imidazopyrazines |
| ES2555261T3 (es) | 2010-06-01 | 2015-12-30 | Bayer Intellectual Property Gmbh | Imidazopirazinas sustituidas |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| US9284317B2 (en) | 2010-12-17 | 2016-03-15 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors |
| JP5822944B2 (ja) | 2010-12-17 | 2015-11-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン |
| ES2530802T3 (es) | 2010-12-17 | 2015-03-06 | Bayer Ip Gmbh | Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos |
| JP2013545779A (ja) | 2010-12-17 | 2013-12-26 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン |
| CN103415518A (zh) | 2010-12-17 | 2013-11-27 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪 |
| CA2821834A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
-
2011
- 2011-08-25 TW TW100130542A patent/TWI541243B/zh not_active IP Right Cessation
- 2011-09-06 PH PH1/2013/500454A patent/PH12013500454A1/en unknown
- 2011-09-06 US US13/822,175 patent/US9255100B2/en not_active Expired - Fee Related
- 2011-09-06 PE PE2013000392A patent/PE20131164A1/es not_active Application Discontinuation
- 2011-09-06 DK DK11751910.8T patent/DK2614063T3/en active
- 2011-09-06 ES ES11751910.8T patent/ES2568220T3/es active Active
- 2011-09-06 CA CA2810755A patent/CA2810755A1/en not_active Abandoned
- 2011-09-06 SI SI201130761A patent/SI2614063T1/sl unknown
- 2011-09-06 MA MA35720A patent/MA34516B1/fr unknown
- 2011-09-06 AU AU2011298844A patent/AU2011298844B2/en not_active Ceased
- 2011-09-06 KR KR1020137009011A patent/KR20140032337A/ko not_active Ceased
- 2011-09-06 HR HRP20160360TT patent/HRP20160360T1/hr unknown
- 2011-09-06 WO PCT/EP2011/065368 patent/WO2012032031A1/en not_active Ceased
- 2011-09-06 JP JP2013527575A patent/JP5824050B2/ja not_active Expired - Fee Related
- 2011-09-06 EA EA201390339A patent/EA023420B1/ru not_active IP Right Cessation
- 2011-09-06 ME MEP-2016-63A patent/ME02389B/me unknown
- 2011-09-06 HU HUE11751910A patent/HUE028771T2/en unknown
- 2011-09-06 MX MX2013002713A patent/MX2013002713A/es active IP Right Grant
- 2011-09-06 RS RS20160221A patent/RS54661B1/sr unknown
- 2011-09-06 EP EP11751910.8A patent/EP2614063B1/en active Active
- 2011-09-06 NZ NZ607904A patent/NZ607904A/en not_active IP Right Cessation
- 2011-09-06 AP AP2013006790A patent/AP3607A/xx active
- 2011-09-06 MY MYPI2013700375A patent/MY185139A/en unknown
- 2011-09-06 CN CN201180054217.5A patent/CN103370318B/zh not_active Expired - Fee Related
- 2011-09-06 PL PL11751910T patent/PL2614063T3/pl unknown
- 2011-09-06 CU CUP2013000033A patent/CU24187B1/es active IP Right Grant
- 2011-09-06 BR BR112013005679A patent/BR112013005679A2/pt not_active IP Right Cessation
- 2011-09-06 SG SG2013016480A patent/SG188417A1/en unknown
- 2011-09-07 SA SA111320735A patent/SA111320735B1/ar unknown
- 2011-09-08 UY UY0001033598A patent/UY33598A/es unknown
- 2011-09-09 AR ARP110103294A patent/AR082946A1/es unknown
-
2013
- 2013-03-05 IL IL225058A patent/IL225058A/en active IP Right Grant
- 2013-03-07 ZA ZA2013/01756A patent/ZA201301756B/en unknown
- 2013-03-08 EC ECSP13012752 patent/ECSP13012752A/es unknown
- 2013-03-08 DO DO2013000054A patent/DOP2013000054A/es unknown
- 2013-03-08 CO CO13047157A patent/CO6720961A2/es active IP Right Grant
- 2013-03-08 CR CR20130102A patent/CR20130102A/es unknown
-
2016
- 2016-04-12 CY CY20161100294T patent/CY1117352T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007038314A2 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| WO2011013729A1 (ja) * | 2009-07-30 | 2011-02-03 | オンコセラピー・サイエンス株式会社 | Ｔｔｋ阻害作用を有する縮合イミダゾール誘導体 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103370318B (zh) | 取代的咪唑并哒嗪 | |
| CN103687858B (zh) | 作为mknk1激酶抑制剂的氨基取代的咪唑并哒嗪 | |
| CN104114559B (zh) | 氨基取代的咪唑并哒嗪 | |
| CN103717604B (zh) | 取代的氨基咪唑并哒嗪 | |
| CN103814029B (zh) | 取代的咪唑并哒嗪 | |
| CN103958515B (zh) | 氨基取代的咪唑并哒嗪 | |
| CN104797585B (zh) | 氨基咪唑并哒嗪 | |
| CN102971321B (zh) | 咪唑并吡嗪 | |
| US9745304B2 (en) | Amidoimidazopyridazines as MKNK-1 kinase inhibitors | |
| CN103038235B (zh) | 取代的咪唑并吡嗪 | |
| CN103429592A (zh) | 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪 | |
| CN103582632B (zh) | 取代的苯并咪唑 | |
| JP5951750B2 (ja) | 置換イミダゾピリジン類およびその中間体 | |
| CN103764656A (zh) | 杂环基氨基咪唑并哒嗪 | |
| CN102596932A (zh) | 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉 | |
| CN103415518A (zh) | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪 | |
| JP2017503809A (ja) | アミド置換イミダゾピリダジン | |
| CN103649087B (zh) | 取代的咪唑并吡啶及其中间体 | |
| HK1187623B (en) | Substituted imidazopyridazines | |
| TW201406760A (zh) | 胺取代咪唑并嗒□ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1187623 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1187623 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160420 Termination date: 20180906 |